Status:
UNKNOWN
D-Serine Monotherapy for Schizophrenia
Lead Sponsor:
Herzog Hospital
Conditions:
Schizophrenia
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
N-methyl-D-aspartate receptor (NMDAR) agonist, added to classical or atypical antipsychotic medication, has reduced negative, depressive, and cognitive symptomatology. We will be investigating the eff...
Eligibility Criteria
Inclusion
- DSM-IV criteria for chronic schizophrenia
- Treatment resistant
- aged 18-70
- Two months on stable risperidone dose
- PANSS positive symptom cluster score \>20
- PANSS negative symptom cluster score \>22
Exclusion
- Substance abuse
- Concurrent DSM IV axis I disorder
- Serious medical disorder
- Concurrent drug therapy that can obscure the effect of risperidone or DSR.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00215917
Last Update
May 3 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Herzog Hospital, Department of Psychiatry
Jerusalem, Israel, 91351